Perspectives in Medical Research

References

1. https://www.who.int/emergencies/diseases/novelcoronavirus-2019
2. https://www.mygov.in/covid-19/
3. Wuhan Municipal Health Commission. Report of Clustering Pneumonia of Unknown etiology in Wuhan city, 2019. http://wjw.wuhan.gov.cn/front/web/showDetail/ 2019123108989
4. Zhu N, Zhang D, Wang W, et al. a novel corona virus from patients with pneumonia in China 2019. N Engl J Med. 2020;382(8):727-733 5. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel corona virus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574
6. Zhou P, yang XL, Wang XG, et al. A pneumonia outbreak associated with a new corona virus of probable bat origin. Nature.2020;579:270-273
7. Javier A James, Nicole M Andre, et al. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses
8. Xinhua. China’s CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan. https:// www.xinhuanet.com/2020-01/27/ c_1125504355.htm
9. https://www.who.int/director-general/speeches/detail/ who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid-19---11-march-2020
10. Paules CI, Marston HD, Fauci AS: Coronavirus infectionsmore than just the common cold . JAMA. 2020, 323:707- 708. 10.1001/jama.2020.0757
11. Richman DD, Whitley RJ,Heyden FG. Clinical Virology,4th ed. Washington: ASM Press;2016
12. Luk HK, Li X, Fung J, Lau SK, Woo PC. Molecular epidemiology, evolution and phylogeny of SARS corona virus. Infection, Genetics and Evolution 2019;71:21-30
13. Li F. Structure, function and evolution of corona virus spike proteins. Annu Rev Virol. 2016;3(1):23237-261
14. Lu g, Wang Q, Gao GF. Bat-to-Human: spike features determining ‘host jump’of corona viruses SARS-CoV, MERS-CoV, and beyond. Trends microbial. 2015;23(8):468- 478
15. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019 nCoV spike in the prefusion confirmation. Science. 2020;367;1260-1263
16. Hoffman M. et al SARS CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.e8 (2020).
17. Sungnak, W et al. SARS CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 26, 681-687 (2020)
18. Hamming I, Timens W, Bulthuis ML, et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS CoV, A first step in understanding SARS pathogenesis”. The Journal of Pathology. 203(2):631-7. Doi:10.1002/path.1570
19. Qi, F., Qian, S., Zhang, S. & Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 526, 135–140 (2020).
20. Pan, X. W. et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 46, 1114–1116 (2020).
21. Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035.e19 (2020).
22. Varga, A. et al. Endothelial cell infection and endothelilitis in COVID-19. Lancet 395, 1417–1418 (2020)
23. Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013).
24. Levi, M. & van der Poll, T. Coagulation and sepsis. Thromb. Res. 149, 38–44 (2017).
25. Bikdeli, B. et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb. Haemost. https://doi.org/10.1055/s-0040-1713152 (2020).
26. Li, H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395, 1517–1520 (2020).
27. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846–848 (2020).
28. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033– 1034 (2020).
29. Huang, K. J. et al. An interferon-?-related cytokine storm in SARS patients. J. Med. Virol. 75, 185–194 (2005).
30. Gallagher, P. E., Ferrario, C. M. & Tallant, E. A. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 295, H2373–H2379 (2008).
31. Tavazzi, G. et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 22, 911– 915 (2020).
32. Walters, T. E. et al. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Ep Europace 19, 1280–1287 (2017).
33. Repessé, X. & Vieillard-Baron, A. Right heart function during acute respiratory distress syndrome. Ann. Transl. Med. 5, 295–295 (2017).
34. Ullah, W., Saeed, R., Sarwar, U., Patel, R. & Fischman, D.L. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep. https://doi.org/ 10.1016/j.jaccas.2020.04.008 (2020).
35. Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury 1 insevere and very severe patients with 2019 novel coronavirus disease. J Infect 2020 Mar 21. pii: S0163-4453(20)30149-3.
36. Pan, L. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am. J. Gastroenterol. 115, 766–773 (2020).
37. Mao, R. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 667–678 (2020).
38. Redd, W.D. et al. Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: a multicenter cohort study. Gastroenterology https://doi.org/10.1053/ j.gastro.2020.04.045 (2020).
39. Pan L, Mu M, Ren HG, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115(5):766–73.
40. Gao QY, Chen YX, Fang JY. 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis 2020:125–6.
41. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. 2020;9(1):386–9.
42. Naicker, S. et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 97, 824–828 (2020).
43. Cheng, Y. et al. Kidney disease is associated with inhospital death of patients with COVID-19. Kidney Int. 97, 829–838 (2020)
44. Hirsch, J.S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. https://doi.org/ 10.1016/j.kint.2020.05.006 (2020).
45. Kissling, S. et al. Collapsing glomerulopathy in a COVID19 patient. Kidney Int. https://doi.org/10.1016/ j.kint.2020.04.006 (2020)
46. Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O. & Sharshir, M. A. Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19). Kidney Int. Rep. 5, 935–939 (2020).
47. Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035.e19 (2020)
48. Lechien, J.R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol. https:// doi.org/10.1007/s00405-020-05965-1. (2020).
49. Spinato, G. et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. J. Am. Med. Assoc. 323, 2089–2090 (2020).
50. Vaira, L. A. et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head. Neck 42, 1252–1258 (2020).
51. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033– 1034 (2020)
52. Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017).
53. Terpos, E. et al. Hematological findings and complications of COVID-19. Am. J. Hematol. 95, 834–847 (2020).
54. Fan, B.E. et al. Hematologic parameters in patients with COVID-19 infection. Am. J. Hematol. https://doi.org/ 10.1002/ajh.25774 (2020).
55. Lippi, G., Plebani, M. & Henry, B. M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin. Chim. Acta 506, 145–148 (2020).
56. Bhatraju, P. K. et al. Covid-19 in critically ill patients in the Seattle region — case series. N. Engl. J. Med. 382, 2012–2022 (2020).
57. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020)
58. Petrilli, C. M. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 369, m1966 (2020).
59. Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844–847 (2020).
60. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).
61. Zhang, C., Shi, L. & Wang, F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 5, 428–430 (2020).
62. Li, H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395, 1517–1520 (2020).
63. Wander, P., Epstein, M. & Bernstein, D. COVID-19 presenting as acute hepatitis. Am. J. Gastroenterol. 115, 941–942 (2020)
64. Liang, W. et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2020.2033 (2020).
65. Chow, N. et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 382–386 (2020).
66. Cummings, M. J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395, 1763–1770 (2020).
67. Li, J. et al. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes. Metab. https://doi.org/ 10.1111/dom.14057 (2020).
68. Eizirik, D. L. & Darville, M. I. Beta-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50, S64–S69 (2001).
69. Yang, J.-K., Lin, S.-S., Ji, X.-J. & Guo, L.-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 47, 193–199 (2010).
70. Simonnet, A. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity https:/ /doi.org/10.1002/oby.2283 (2020).
71. McClean, K. M., Kee, F., Young, I. S. & Elborn, J. S. Obesity and the lung: Epidemiol. Thorax 63, 649–654 (2008).
72. Hibbert, K., Rice, M., Malhotra, A. & Obesity, ARDS. Chest 142, 785–790 (2012).
73. Rajala, M. W. & Scherer, P. E. Minireview: the adipocyteat the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765–3773 (2003).
74. Recalcati, S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. Dermatol. Venereol. 34, e212– e213 (2020)
75. Chen S, Huang B, Luo D, et al. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases. Chinese journal of pathology 2020;49:E005.
76. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. American journal of obstetrics gynecology 2004;191(1):292–7.
77. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020;9(1):51–60.